Клиническое значение молекулярно-биологических маркеров в прогнозировании хирургического лечения рака пищевода
Диссертация
Так, для пациентов, которым планируется только хирургическое лечение, выявление неблагоприятных прогностических маркеров, сопряженных с высоким риском послеоперационного прогрессирования, может способствовать пересмотру тактики лечения в пользу проведения неоадьювантной и/или адьювантной терапии, в том числе, с применением таргетных препаратов. Кроме того, молекулярные маркеры могут оказаться… Читать ещё >
Содержание
- Актуальность темы
- Цель работы
- Задачи исследования
- Научная новизна
- Практическая значимость
- Публикации
- ГЛАВА I. ОБЗОР ЛИТЕРАТУРЫ
- 1. Рак пищевода — общие сведения (эпидемиология, методы и результаты лечения)
- 2. Прогнозирование продолжительности жизни больных раком пищевода
- 3. Функции и клиническое значение молекулярно-биологических маркеров при плоскоклеточном раке пищевода
- 3. 1. Рецепторы эпидермального фактора роста 1и2 типа
- 3. 1. 1. Функции рецепторов эпидермального фактора роста
- 3. 1. 2. Клиническое значение Е6РЯ и -lER~2 при ПРП
- 3. 2. Факторы связанные с адгезией: Е-кадгерин и бета-катенин
- 3. 2. 1. Функции Е-кадгерина, бета-катенина и кадгерин-катенинового комплекса
- 3. 2. 2. Клиническое значение Е-кадгерина и бета-катенина при ПРП
- 3. 3. Молекулы адгезии семейства С
- 3. 3. 1. Функции Сй
- 3. 3. 2. Клиническое значение Сй44 при ПРП
- 3. 1. Рецепторы эпидермального фактора роста 1и2 типа
Список литературы
- Албертс Б., Брей Д., Льюис Д. и др. Молекулярная биология клетки: В 3-х т. 2-е изд. перераб. М75 и доп. Т. 2. // М: Мир 1993. — 539 е., ил. ISBN 503−1 987−1.
- Давыдов М. И., Аксель Е. М. СТАТИСТИКА ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ В РОССИИ И СТРАНАХ СНГ В 2007 г. // ВЕСТНИК РОНЦ им. Н. Н. Блохина РАМН 2009. — Том 20, № 3 (77), прил. 1 Июль — сентябрь 2009 г.
- Давыдов М. И., Стилиди И. С. Рак пищевода. 2007. 392 стр.
- Мамонтов А. С., Верещагин В. Г. Результаты хирургического лечения рака грудного отдела пищевода. //Хирургия 1986. — № 7. — С. 93D98.
- Пальцев М. А., Иванов А. А. Межклеточные взаимодействия. // М.: Медицина 1995. — П14'224с., ил. ISBN 5−225−2 178−6.
- Стилиди И. С., Бохян В. Ю., Тер-Ованесов М. Д. Результаты и перспективы хирургического лечения больных раком грудного отдела пищевода. // ПРАКТИЧЕСКАЯ ОНКОЛОГИЯ 2003. — Т. 4, № 2, стр.70−75.
- Aberle Н., Butz S, Stappert J. et all Assembly of the4 cadherin-catenin-complex in vitro with recombinant proteins. // J Cell Sci 1994. — Dec- 107 (Pt 12):3655−63.
- Akamatsu M., Matsumoto Т., Oka K. et al. c-erbB-2 oncoprotein expression related-to chemoradioresistance in esophageal squamous cell carcinoma. // Int J Radiat Oncol Biol Phys 2003. — Dec 1 -57(5): 1323−7.
- Aloia T. A., Harpole D. H., Jr., Reed С. E. et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. // Ann Thorac Surg -2001. Sep-72(3):859−66.
- Altorki N., Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? // Ann Surg 2001. — Nov-234(5):581−7.
- Asakura H., Hashimoto Т., Zenda S. et al. Analysis of dose-volume histogram parameters ч for radiation pneumonitis after definitive concurrentchemoradiotherapy for esophageal cancer. // Radiother Oncol 2010. -May-95(2):240−4.
- Barker N. The canonical Wnt/beta-catenin signalling pathway. // Methods MolBiol- 2008. -.
- Bartolazzi A., Peach R., Aruffo A. et al. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. // J Exp Med- 1994. Jul l-180(l):53−66.
- Bazil V., Strominger J. L. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD 16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD 16. // J Immunol 1994. — Feb 1- 152(3): 1314−22.
- Berger B., Belka C. Evidence-based radiation oncology: oesophagus. // Radiother Oncol 2009. — Aug-92(2):276−90.
- Berrino F., Sant M., Verdecchia A. et al. Survival of cancer patients in Europe. // The Eurocare Study, IARC, Lyon 1995. — pp. 1−463.
- Boag J. W. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. I/JR Stat Soc 1949. — (Ser B), 11:15−53.
- Borland G., Ross J. A., Guy K. Forms and functions of CD44. // Immunology 1998. — Feb-93(2): 139−48.
- Bosset J. F., Gignoux M., Triboulet J. P. et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. UN Engl J Med- 1997. Jul 17−337(3):161−7.
- Bourguignon L. Y., Zhu H., Chu A. et al. Interaction between the adhesion receptor, CD44, and the oncogene product, pl85HER2, promotes human ovarian tumor cell activation. IIJ Biol Chem 1997. — Oct 31−272(44):27 913−8.
- Boyle P., Levin B. // World Cancer Report 2008. -.
- Braun K. M. Cutaneous cancer stem cells: beta-catenin strikes again. // Cell Stem Cell 2008. — May 8−2(5):406−8.
- Brembeck F. H., Schwarz-Romond T., Bakkers J. et al. Essential role of BCL9−2 in the switch between beta-catenin's adhesive and transcriptional functions. // Genes Dev 2004. — Sep 15−18(18):2225−30.
- Brieher W. M., Yap A. S., Gumbiner B. M. Lateral dimerization is required for the homophilic binding activity of C-cadherin. // J Cell Biol 1996. -Oct-135(2):487−96.
- Cadigan K. M., Peifer M. Wnt signaling from development to disease: insights from model systems. // Cold Spring Harb Perspect Biol 2009. -Aug-l (2):a002881.
- Chai L. X., Sun K. L., Guo L. P. et al. Expression of ezrin and CD44-v6 in human esophageal squamous cell carcinoma and its clinical significance. // Zhonghua ZhongLiu Za Zhi 2007. — Sep-29(9):685−8.
- Chen C. P., Posy S., Ben-Shaul A. et al. Specificity of cell-cell adhesion by classical cadherins: Critical role for low-affinity dimerization through beta-strand swapping. II Proc Natl Acad Sci USA 2005. — Jun 14−102(24):8531−6.
- Chikamatsu K., Okamotoa A., Sakakurab K. et al. Immunological properties of CD44+ cancer stem cells in squamous cell carcinoma of the head and neck. // Oral Oncology Supplement 2009. — Volume 3, Issue 1, July 2009, Pages 205−206.
- Chung Y., Lam A. K., Luk J. M. et al. Altered E-cadherin expression and pl20 catenin localization in esophageal squamous cell carcinoma. // Ann Surg Oncol 2007. — Nov- 14(11):3260−7.
- Clevers H. Wnt/beta-catenin signaling in development and disease. // Cell -2006. Nov 3−127(3):469−80.
- Cox D., Oakes D. Analysis of survival data. // New York, NY, Chapman Hall -1984. -.
- De Marzo A. M., Bradshaw C., Sauvageot J. et al. CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. // Prostate 1998. — Feb 15−34(3): 162−8.
- Dreilich M., Wanders A., Brattstrom D. et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. // Dis Esophagus 2006. — 19(4):224−31.
- Edge S. B., Byrd D. R., Compton C. C. et al. AJCC Cancer Staging Manual. // Springer-Verlag 2009. — p.103−15.
- Forastiere A. Multimodality treatment of esophagus cancer: current status and future perspectives in the United States. // Esophagus 2010. — Vol. 7, No. 1. (1 March 2010), pp. 1−6.
- Fraser J. R., Laurent Т. C., Laurent U. B. Hyaluronan: its nature, distribution, functions and turnover. H J Intern Med 1997. — Jul-242(l):27−33.
- Furuyama H., Arii S., Mori A. et al. Role of E-cadherin in peritoneal dissemination of the pancreatic cancer cell line, panc-1, through regulation of cell to cell contact. // Cancer Lett 2000. — Sep l-157(2):201−9.
- Gamel J. W., Greenberg R. A., McLean I. W. A stable linear algorithm for fitting the lognormal model to survival data. // Comput Biomed Res 1988. -Feb-21(l):38−47.
- Gao A. C., Lou W., Dong J. T. et al. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 1 lpl3. // Cancer Res 1997. — Mar l-57(5):846−9.
- Garrod D. R., Merritt A. J., Nie Z. Desmosomal cadherins. // Curr Opin Cell Biol 2002. — Oct-14(5):537−45.
- Gavert N., Ben-Ze'ev A. beta-Catenin signaling in biological control and cancer. // J Cell Biochem 2007. — Nov 1- 102(4):820−8.
- Gibault L., Metges J. P., Conan-Charlet V. et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. II Br J Cancer 2005. — Jul 11−93(1):107−15.
- Giles R. H., van Es J. H., Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. // Biochim Biophys Acta 2003. — Jun 5−1653(l):l-24.
- Gottardi C. J., Gumbiner B. M. Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes. // J Cell Biol 2004. — Oct 25−167(2):339−49.
- Grady W. M., Willis J., Guilford P. J. et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. // Nat Genet -2000. -Sep-26(l): 16−7.
- Gu H., Shang P., Zhou C. Expression of CD44v6 and P16 gene in esophageal carcinoma in situ hybridization. // Journal of XVan Jiaotong University (Medical Sciences) 2003. — Pages 468−470+486.
- Gumbiner B. M. Regulation of cadherin-mediated adhesion in morphogenesis. II Nat. Rev. Mol. Cell Biol. 2005. — Aug-6(8):622−34.
- Gumbiner B. M. Regulation of cadherin adhesive activity. // J Cell Biol -2000. Feb 7−148(3):399−404.
- Gunthert U., Hofmann M., Rudy W. et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. // Cell 1991. — Apr 5−65(l):13−24.
- Hanahan D., Weinberg R. A. The hallmarks of cancer. // Cell 2000. Jan 7−100(l):57−70.
- Hanawa M., Suzuki S., Dobashi Y. et al. EGFR protein overexpression and' gene amplification in squamous cell carcinomas of the esophagus. // Int J Cancer -2006.-Mar 1- 118(5): 1173−80.
- Hardwick R. H., Barham C. P., Ozua P. et ah Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma- no correlation with prognosis. // Eur J Surg Oncol 1997. — Feb-23(l):30−5.
- Harrington K. J, Syrigos K. N. The role of E-cadherin-catenin complex: more than an intercellular glue? I I Ann Surg Oncol 2000. — Dec-7(10):783−8.
- Hartmann* G., Prospero T., Brinkmann V. et al. Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. // CurrBiol 1998. — Jan 29−8(3): 125−34.
- Hatzfeld M. The pl20'family of cell adhesion molecules. II Eur J Cell Biol -2005. Mar-84(2−3):205−14.
- Herbst R. S. Review of epidermal growth factor receptor biology. // Int J Radiat Oncol Biol Phys 2004. — 59(2 Suppl):21−6.
- Herceg Z., Hainaut P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. // Mol Oncol 2007. — Jun-l (l):26−41.
- Herzig M., Savarese F., Novatchkova M. et al. Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling. // Oncogene 2007. — Apr 5−26(16):2290−8.
- Higuchi K., Koizumi W., Tanabe S. et al. Current management of esophageal squamous-cell carcinoma in Japan and other countries. // Gastrointest Cancer Res -2009.-Jul-3(4): 153−61.
- Hirokawa N., Keller T. C., 3rd, Chasan R. et al. Mechanism of brush border contractility studied by the quick-freeze, deep-etch method. // J Cell Biol 1983. -May-96(5): 1325−36.
- Hofstetter W., Correa A. M., Bekele N. et al. Proposed modification of nodal status in AJCC esophageal cancer staging system. // Ann Thorac Surg 2007. -Aug-84(2):365−73- discussion 374−5.
- Hoschuetzky H., Aberle H., Kemler R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. // J Cell Biol 1994. — Dec- 127(5): 1375−80.
- Howng S. L., Wu C. H., Cheng T. S. et al. Differential expression of Wnt genes, beta-catenin and E-cadherin in human brain tumors. // Cancer Lett 2002. -Sep 8−183(1):95−101.
- Hua P., Huang H., Zhang H. Expression of CD44 and nm23 gene protein in esophageal cancer. // Chinese Journal of Clinical Oncology 1999. — Volume 26, Issue 9,1999, Pages 666−669.
- Huang H., He X. Wnt/beta-catenin signaling: new (and old) players and new insights. // Curr Opin Cell Biol 2008. — Apr-20(2): 119−25.
- Huber A. H., Weis W. I. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. // Cell -2001. May 4−105(3):391−402.
- Hulscher J. B., Tijssen J. G., Obertop H. et al. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. // Ann Thorac Surg -2001. Jul-72(l):306−13.
- Hynes N. E., Stern D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. // Biochim Biophys Acta 1994. — Dec 30- 1198(2−3): 165−84.
- Ide H., Eguchi R., Nakamara T.
- Ikeda Y., Ozawa S., Ando N. et al. Meanings of c-erbB and int-2 amplification in superficial esophageal squamous cell carcinomas. // Ann Thorac Surg 1996. — Sep-62(3):835−8.
- Inada S., Koto T., Futami K. et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). // Surg Today 1999. — 29(6):493−503.
- Ishikura S., Nihei K., Ohtsu A. et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. // J Clin Oncol- 2003. Jul 15−21(14):2697−702.
- Jaggi M., Rao P. S., Smith D. J. et al. E-cadherin phosphorylation by protein kinase Dl/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. // Cancer Res 2005. — Jan 15−65(2):483−92.
- Jorissen R. N. s Walker F., Pouliot N. et al. Epidermal growth factor receptor: mechanisms of activation and signalling. // Exp Cell Res 2003. — Mar 10−284(l):31−53.
- Kadowaki T., Shiozaki H., Inoue M. et al. E-cadherin and alpha-catenin expression in human esophageal cancer. // Cancer Res 1994. — Jan l-54(l):291−6.
- Kalomiris E. L., Bourguignon L. Y. Mouse T lymphoma cells contain a transmembrane glycoprotein (GP85) that binds ankyrin. // J Cell Biol 1988. -Feb-106(2):319−27.
- Kaneko K., Kumekawa Y., Makino R. et al. EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. // Front Biosci 2010. — Jan 1- 15:65−72.
- Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. IIJ Am Stat Assoc 1958. — 53: 457−481.
- Kataoka H. EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. // J Dermatol Sci 2009. -Dec-56(3): 148−53.
- Kato H.5 Miyazaki T., Nakajima M. et al. Prediction of hematogenous recurrence in patients with esophageal carcinoma. // Jpn J Thorac Cardiovasc Surg 2003. — Nov-51(ll):599−608.
- Kawaguchi Y., Kono K., Mimura K. et al. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. II Br J Cancer 2007. — Aug 20−97(4):494−501.
- Kawano Y., Okamoto I., Murakami D. et al. Ras oncoprotein induces CD44 cleavage through phosphoinositide 3-OH kinase and the rho family of small G proteins. IIJ Biol Chem 2000. — Sep 22−275(38):29 628−35.
- Kelsen D. P., Ginsberg R., Pajak T. F. et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. // N Engl J Med- 1998. Dec 31 -339(27): 1979−84.
- Kim S. H., Nakagawa H., Navaraj A. et al. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. // Cancer Res 2006. — Nov 1−66(21): 10 415−24.
- Kimelman D., Xu W. beta-catenin destruction complex: insights and questions from a structural perspective. // Oncogene 2006. — Dec 4−25(57):7482−91.
- Kimura Y., Shiozaki H., Doki Y. et al. Cytoplasmic beta-catenin in esophageal cancers. // Int J Cancer 1999. — Apr 20−84(2): 174−8.
- Kudo J., Nishiwaki T., Haruki N. et al. Aberrant nuclear localization of beta-catenin without genetic alterations in beta-catenin or Axin genes in esophageal cancer. // World J Surg Oncol 2007. — Feb 19−5:21.
- Kunisaki C., Shimada H., Akiyama H. et al. Prognostic factors in esophageal cancer. // Hepatogastroenterology 2004. — May-Jun-51(57):736−40.
- Kuwano H., Nishimura Y., Ohtsu A. et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus: April 2007 edition: Part II edited by the Japan Esophageal Society. // Esophagus 2008. — Volume 5, Issue 3, September2008, Pages 117−132.
- Law S. Prognostication for patients with esophageal cancer. // Esophagus2009.-6:215−219.
- Legg J. W., Lewis C. A., Parsons M. et al. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. // Nat Cell Biol 2002. — Jun-4(6):399−407.
- Li D. M., Li S. S., Zhang Y. H. et al. Expression of human chorionic gonadotropin, CD44v6 and CD44v4/5 in esophageal squamous cell carcinoma. // World J Gastroenterol 2005. — Dec 21−11(47):7401−4.
- Lickert H., Bauer A., Kemler R. et al. Casein kinase II phosphorylation of E-cadherin increases E-cadherin/beta-catenin interaction and strengthens cell-cell adhesion. // J Biol Chem 2000. — Feb 18−275(7):5090−5.
- Lilien J., Balsamo J-, Arregui C. et al. Turn-off, drop-out: functional- state switching of cadherins. //DevDyn 2002. — May-224(l): 18−29.
- Limpert E., Stahel W. A., Abbt M. Log-normal Distributions across the Sciences: Keys and Clues. // Bioscience 2001. — Vol. 51, No. 5. (1 May 2001), pp. 341−352.
- Linggi B., Carpenter G. ErbB receptors: new insights on mechanisms and biology. // Trends Cell Biol 2006. — Dec- 16(12):649−56.
- Liu W. K., Chu Y. L., Zhang F. et al. The relationship between HPV16 and expression of CD44v6, nm23Ul in esophageal squamous cell carcinoma. // Arch Virol 2005. — May- 150(5):991−1001.
- Liu W. K., Fu Q., Li Y. M. et al. The relationship between cyclooxygenasc-2, CD44v6, and' nm23Hl in esophageal squamous cell carcinoma. // Onkologie -2009. Oct-32(10):574−8.
- Long W., Yi P, Amazit L. et al. SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. // Mol Cell 2010. — Feb 12−37(3):321−32.
- Loric S., Paradis V., Gala J. L. et al. Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. // Eur J Cancer 2001. — Aug-37(12): 1475−81.
- Lowy A. M., Knight Jl, Groden J. Restoration of E-cadhcrin/beta-catenin expression in pancreatic cancer cells inhibits growth by induction of apoptosis. // Surgery 2002. — Aug-132(2): 141−8.
- Malthaner R., Wong R. K., Spithoff K. Preoperative or postoperative therapy for resectable oesophageal cancer: an updated practice guideline. // Clin Oncol (R Coll Radiol) 2010. — May-22(4):250−6.
- Malthaner R. A., Wong R. K., Rumble R. B. et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline. // BMC Cancer 2004. — Sep 24−4:67.
- Malthaner R. A., Wong R. K., Rumble R. B. et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. // BMC Med- 2004. Sep 24−2:35.
- Mandard A. M., Hainaut P., Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. // Mutat Res 2000. — Apr-462(2−3):335−42.
- Marangoni E., Lecomte N., Durand L. et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. // Br J Cancer 2009. — Mar 24- 100(6):918−22.
- Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. // Lancet 2002. — 359:1727−33.
- Metzger R., Schneider P. M., Warnecke-Eberz U. et al. Molecular biology of esophageal cancer. // Onkologie 2004. — Apr-27(2):200−6.
- Miettinen P. J., Berger J. E., Meneses J. et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. // Nature -1995. Jul 27−376(6538):337−41.
- Mimura K., Kono K., Hanawa M. et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. // Br J Cancer 2005. — Apr 11−92(7): 1253−60.
- Miyata M., Shiozaki H.5 Iihara K. et al. Relationship between E-cadherin expression and lymph node metastasis in human esophageal cancer. // International Journal of Oncology 1994. — Volume 4, Issue 1, 1994, Pages 61−65.
- Morrison H., Sherman L. S., Legg J. et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. // Genes Dev 2001. — Apr 15−15(8):968−80.
- Morrison H., Sperka T., Manent J. et al. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. // Cancer Res ~ 2007. Jan 15−67(2):520−7.
- Mosimann C., Hausmann G., Basler K. Beta-catenin hits chromatin: regulation of Wnt target gene activation. // Nat Rev Mol Cell Biol 2009. -Apr-10(4):276−86.
- Naor D., Nedvetzki S., Golan I. et al. CD44 in cancer. // Crit Rev Clin Lab Sci 2002. — 2002 Nov-39(6):527−79.
- Naor D., Sionov R. V., Ish-Shalom D. CD44: structure, function, and, association with the malignant process. // Adv Cancer Res 1997. — 1997−71:241−319.
- Nelson W. J. Regulation of cell-cell adhesion by the cadherin-catenin complex. // Biochem Soc Trans 2008. — Apr-36(Pt 2): 149−55.
- Nozoe T., Kohnoe S., Ezaki T. et al. Significance of immunohistochemical over-expression of CD44v6 as an indicator of malignant potential in esophageal squamous cell carcinoma. IIJ Cancer Res Clin Oncol 2004. — Jun-130(6):334−8.
- Okamoto I., Kawano Y., Matsumoto M. et al. Regulated CD44 cleavage under the control of protein kinase C, calcium influx, and the Rho family of small G proteins. U J Biol Chem 1999. — Sep 3−274(36):25 525−34.
- Okamoto I., Tsuiki H., Kenyon L. C. et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. // Am J Pathol 2002. -Feb-160(2):441−7.
- Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. // Eur J Cancer 2010. — Volume 46, Issue 7, May 2010, Pages 1271−1277.
- Orian-Rousseau V., Chen L., Sleeman J. P. et al. CD44 is required for two consecutive steps in HGF/c-Met signaling. // Genes Dev 2002. — Dec l-16(23):3074−86.
- Overduin M., Harvey T. S., Bagby S. et al. Solution structure of the epithelial cadherin domain responsible for selective cell adhesion. // Science 1995. — Jan 20−267(5196):386−9.
- Ozawa M., Baribault H., Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. HEMBOJ- 1989. Jun-8(6):1711−7.
- Peck D., Isacke C. M. Hyaluronan-dependent cell migration can be blocked by a CD44 cytoplasmic domain peptide containing a phosphoserine at position 325. IIJ Cell Sci 1998. — Jun-lll (Pt 11): 1595−601.
- Peto R., Reto J. Asymptotically efficient invariant procedures. // JR Stat Soc -1972. 135: 185−206.
- Pollard T. D., Borisy G. G. Cellular motility driven by assembly and disassembly of actin filaments. // Cell 2003. — Feb 21−112(4):453−65.
- Ponta H., Sherman L., Herrlich P. A. CD44: from adhesion molecules to signalling regulators. // Nat Rev Mol Cell Biol 2003. — Jan-4(l):33−45.
- Prenzel N., Fischer O. M., Streit S. et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. II Endocr Relat Cancer 2001. — Mar-8(l): 11−31.
- Pure E., Assoian R. K. Rheostatic signaling by CD44 and hyaluronan. // Cell Signal 2009. — May-21(5):651−5.
- Reichelt U., Duesedau P., Tsourlakis M. et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. // Mod Pathol 2007. — Jan-20(l): 120−9.
- Rhee J., Buchan T., Zukerberg L. et al. Cables links Robo-bound Abl kinase to N-cadherin-bound beta-catenin to mediate Slit-induced modulation of adhesion and transcription. //Nat Cell Biol 2007. — Aug-9(8):883−92.
- Rhee J., Lilien J., Balsamo J. Essential tyrosine residues for interaction of the non-receptor protein-tyrosine phosphatase PTP1B with N-cadherin. // J Biol Chem- 2001. Mar 2−276(9):6640−4.
- Rice T. W., Blackstone E. H., Rusch V. W. 7th Edition of the AJCC Cancer Staging Manual: Esophagus and Esophagogastric Junction. // Ann Surg Oncol -2010.-Apr6.
- Rice T. W., Rusch V. W., Apperson-Hansen C. et al. Worldwide esophageal cancer collaboration. // Dis Esophagus 2009. — 22(1): 1−8.
- Roth M. J., Hu N., Johnson L. L. et al. beta-Catenin splice variants and downstream targets as markers for neoplastic progression of esophageal cancer. // Genes Chromosomes Cancer 2005. — Dec-44(4):423−8.
- Rothberg K. G., Heuser J. E., Donzell W. C. et al. Caveolin, a protein component of caveolae membrane coats. // Cell 1992. — Feb 21−68(4):673−82.
- Roye G. D., Myers R. B., Brown D. et al. CD44 expression in dysplastic epithelium and squamous-cell carcinoma of the esophagus. H Int J Cancer 1996. -Aug 22−69(4):254−8.
- Royston P. The Lognormal Distribution as a Model for Survival Time in Cancer, With an Emphasis on Prognostic Factors. // Statistica Neerlandica 2001.- March 2001, Volume 55, Issue 1, pages 89−104.
- Saeki H., Tanaka S., Sugimachi K. et al. Interrelation between expression of matrix metalloproteinase 7 and beta-catenin in esophageal cancer. // Dig Dis Sci -2002. Dec-47(12):2738−42.
- Schulz W. A., et al. Molecular Biology of Human Cancers. // Springer Science + Business Media 2005. — Print ISBN: 1−4020−3185−8, p.71−90.
- Seiter S., Arch R., Reber S. et al. Prevention of tumor metastasis formation by anti-variant CD44. IIJ Exp Med- 1993. Feb l-177(2):443−55.
- Sherman L. S., Rizvi T. A., Karyala S. et al. CD44 enhances neuregulin signaling by Schwann cells. IIJ Cell Biol 2000. — Sep 4- 150(5): 1071−84.
- Sherr C. J. G1 phase progression: cycling on cue. // Cell 1994. — Nov 18−79(4):551−5.
- Sherrill J. M. Self-phosphorylation of epidermal growth factor receptor is an intermolecular reaction- // Biochemistry 1997. — Oct 21 -36(42): 12 890−6.
- Shimada Y., Sato F. Molecular factors related to> metastasis of esophageal squamous cell carcinoma. // Esophagus 2007. — 4:7−18.
- Shiozaki H., Doki Y., Kawanishi K. et al. Clinical application’of malignancy potential grading as a prognostic factor, of human esophageal* cancers. // Surgery -2000.-May- 127(5):552−61.
- Shitara K., Muro K. Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives. // Gastrointest Cancer Res 2009. -Mar-3(2):66−72.
- Shtivelman E., Bishop J. M. Expression of CD44 is repressed in neuroblastoma cells. // Mol Cell Biol -1991. Nov-l 1(11):5446−53.
- Sneath R. J., Mangham D. C. The normal structure and function of CD44 and its role in neoplasia. // Mol Pathol 1998. — Aug-51(4): 191−200.
- Spratt J. S., Jr. The lognormal frequency distribution and human cancer. // J Surg Res 1969. — Mar-9(3): 151−7.
- Stahl M., Oliveira J. Esophageal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. II Ann Oncol 2009. — May-20 Suppl 4:32−3.
- Stein U., Arlt F., Walther W. et al. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. // Gastroenterology 2006. — Nov- 131(5): 1486−500.
- Stern R., Waugh D. J. J., McClatchey A. et al. HYALURONAN IN CANCER BIOLOGY. // ACADEMIC PRESS 2009. — Chapter 7, Pages 109−125 doi: 10.1016/B978−12 374 178−3.10 007−9.
- Stoecklein N. H., Hosch S. B., Bezler M. et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. // Cancer Cell 2008. — May-13(5):441−53.
- Sudo T., Mimori K., Nagahara H. et al. Identification of EGFR mutations in esophageal cancer. // Eur J Surg Oncol 2007. — Feb-33(l):44−8.
- Sunpaweravong P., Sunpaweravong S., Puttawibul P. et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. // J Cancer Res Clin Oncol 2005. -Feb- 131(2): 111−9.
- Suo Z., Su W., Holm R. et al. Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. // Anticancer Res 1995. — Nov-Dec-15(6B):2797−8.
- Suzuki H., Abo S., Kitamura M. et al. Gene amplification of int-2 and erbB in human esophageal cancer: relationship to clinicopathological variables. // Cancer Invest 1997. — 15(5):411−5.
- Takai Y., Nakanishi H. Nectin and afadin: novel organizers of intercellular junctions. II J. Cell Scl 2003. — Jan l-116(Pt l):17−27.
- Takayama N., Arima S., Haraoka S. et al. Relationship between the Expression of Adhesion Molecules in Primary Esophageal Squamous Cell
- Carcinoma and Metastatic Lymph Nodes. // Anticancer Research 2003. — Volume 23, Issue 6 A, November 2003, Pages 4435−4441.
- Takeichi M. The cadherins: Cell-cell adhesion molecules controlling animal morphogenesis. J J Development 1988. — 102: 639−655.
- Takeichi M. Morphogenetic roles of classic cadherins. // Curr.Opin. Cell Biol. 1995. — Oct-7(5):619−27.
- Takeno S., Noguchi T., Takahashi Y. et al. Assessment of Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma Using TNM Classification Score and Molecular Biological Classification. // Annals of Surgical Oncology2006. 14(4): 1431−1438.
- Takeno S., Noguchi T., Takahashi Y. et al. Assessment of Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma Using TNM Classification Score and Molecular Biological Classification. // Annals of Surgical Oncology2007. 14(4): 1431−1438.
- Thirion P. G., Michiels S., Maitre A. L. et al. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. 1/ J Clin Oncol 2007. — 25: p. 4512.
- Tominaga J., Fukunaga Y., Abelardo E. et al. Defining the function of beta-catenin tyrosine phosphorylation in cadherin-mediated cell-cell adhesion. // Genes Cells 2008. — Jan-13(l):67−77.
- Tremmel M., Matzke A., Albrecht I. et al. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. // Blood 2009. — Dec 10−114(25):5236−44.
- Tsukita S., Oishi K., Sato N. et al. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. // J Cell Biol- 1994. Jul-126(2):391−401.
- Wang L. S., Chow K. C., Chi K. H. et al. Prognosis of esophageal squamous cell carcinoma: analysis of clinicopathological and biological factors. // Am J Gastroenterol- 1999. Jul-94(7): 1933−40.
- Wang W., Xue L., Wang P. Prognostic value of beta-catenin, c-myc, and cyclin D1 expressions in patients with esophageal squamous cell carcinoma. // Med Oncol- 2010. -Feb 9.
- Wedlich. D. The polarising role of cell adhesion molecules, in early development. // Curr Opin Cell Biol 2002. — Oct-14(5):563−8.
- Wei Q., Chen L., Sheng L. et al. EGFR, HER2 and HER3 expression in esophageal primary, tumours and corresponding metastases. // Int J Oncol 2007. -Sep-31(3):493−9.
- Weihua Z., Tsan R., Huang W. C. et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. // Cancer Cell 2008. -May-13(5):385−93.
- Wells A. EGF receptor. U Int J Biochem Cell Biol 1999. — Jun-31(6):637−43.
- Wielenga V. J., Heider K. H., Offerhaus G. J. et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. // Cancer Res 1993. — Oct 15−53(20):4754−6.
- Willert K., Jones K. A. Wnt signaling: is the party in the nucleus? // Genes Dev 2006. — Jun 1−20(11): 1394−404.
- Yamada S., Nelson W. J. Synapses: sites of cell recognition, adhesion and functional specification. // Annu.Rev.Biochem. 2007. — 76,267−294.
- Yang Y., Goldstein B. G., Nakagawa H. et al. Kruppel-like factor 5 activates MEK/ERK signaling via EGFR in primary squamous epithelial cells. // FASEB J -2007. Feb-21(2):543−50.
- Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. // Genes Dev 2000. — Jan 15−14(2): 163−76.
- Yu Q., Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. // Genes Dev -1999. Jan l-13(l):35−48.
- Yu Q., Toole B. P., Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. IIJ Exp Med- 1997. Dec 15−186(12):1985−96.
- Zhang C., Yang H., Li C.-w. CD44+CD24+ as a Potential Cell Surface Marker to Identify Gastric Cancer Stem Cells. // Gastroenterology 2010. -Volume 138, Issue 5, Supplement 1, May 2010, Pages S-759.
- Zhao X. J., Li H., Chen H. et al. Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: relationships with prognosis. // World J Gastroenterol 2003. — Feb-9(2):225−32.